Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Tamminga, Menno, de Wit, Sanne, Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Terstappen, Leon W. M. M., Groen, Harry J. M.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://ncbi.nlm.nih.gov/pubmed/31291995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0649-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires